Global Breast Cancer Predictive Genetic Testing

Breast Cancer Predictive Genetic Testing Comprehensive Study by Type (High Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes), Application (Hospitals, Clinic Center, Pharmaceuticals, Research institutes, Diagnostics laboratories) Players and Region - Global Market Outlook to 2027

Breast Cancer Predictive Genetic Testing Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Breast Cancer Predictive Genetic Testing?
Breast cancer is a subset of the broader breast disease. As a result, typical breast cancer symptoms include the formation of red lumps in the breast and skin lumps. Being overweight, inactive, and drinking too much alcohol are all risk factors for developing breast cancer. Presymptomatic testing is another name for predictive gene testing. Given that this test is completed even before the early signs of the disease or disorder are visible, it allows determining a person's risk of suffering from disorder or disease. Predictive breast cancer gene testing is used to determine a person's risk of developing the disease if they have a family history of it. Early identification of breast cancer allows the patient to be entirely cured and the affected breast to be saved. Since the benefits of early detection of breast cancer have been recognized, governments and non-governmental organisations all over the world have begun to take steps to raise awareness about the disease and early detection tools available in their individual jurisdictions.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledRoche (United States), Thermo Fisher Scientific (United States), PerkinElmer (United States), Quest Diagnostics (United States), Myriad Genetics (United States), Cancer Genetics, Inc. (Italy), OncoCyte Corporation (United States) and NeoGenomics (United States)
CAGR%


The market study is broken down by Type (High Penetrant Genes, Intermediate Penetrant Genes and Low Penetrant Genes), by Application (Hospitals, Clinic Center, Pharmaceuticals, Research institutes and Diagnostics laboratories) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Breast Cancer Predictive Genetic Testing market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Roche (United States), Thermo Fisher Scientific (United States), PerkinElmer (United States), Quest Diagnostics (United States), Myriad Genetics (United States), Cancer Genetics, Inc. (Italy), OncoCyte Corporation (United States) and NeoGenomics (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Breast Cancer Predictive Genetic Testing market by Type, Application and Region.

On the basis of geography, the market of Breast Cancer Predictive Genetic Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
On 8 December 2021, Thermo Fisher Scientific Inc., the world leader in serving science, announced that it has completed its acquisition of PPD, Inc., a leading global provider of clinical research services to the biopharma and biotech industry



Market Trend
  • Advancements In The Medical Science

Market Drivers
  • Increasing Prevalence Of Breast Cancer
  • Increased Number Of Diagnostic Centers

Opportunities
  • Growth In The Healthcare Industry
  • Increased Research And Development Activities

Restraints
  • High Initial Capital Investments
  • The Challenging Task Of Selecting The Most Suitable Genetic Test For Each Patient

Challenges
  • Strict Government Regulations For Predictive Breast Cancer Genetic Tests


Key Target Audience
Breast Cancer Predictive Genetic Testing, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • High Penetrant Genes
  • Intermediate Penetrant Genes
  • Low Penetrant Genes
By Application
  • Hospitals
  • Clinic Center
  • Pharmaceuticals
  • Research institutes
  • Diagnostics laboratories
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence Of Breast Cancer
      • 3.2.2. Increased Number Of Diagnostic Centers
    • 3.3. Market Challenges
      • 3.3.1. Strict Government Regulations For Predictive Breast Cancer Genetic Tests
    • 3.4. Market Trends
      • 3.4.1. Advancements In The Medical Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Breast Cancer Predictive Genetic Testing, by Type, Application and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Breast Cancer Predictive Genetic Testing (Value)
      • 5.2.1. Global Breast Cancer Predictive Genetic Testing by: Type (Value)
        • 5.2.1.1. High Penetrant Genes
        • 5.2.1.2. Intermediate Penetrant Genes
        • 5.2.1.3. Low Penetrant Genes
      • 5.2.2. Global Breast Cancer Predictive Genetic Testing by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinic Center
        • 5.2.2.3. Pharmaceuticals
        • 5.2.2.4. Research institutes
        • 5.2.2.5. Diagnostics laboratories
      • 5.2.3. Global Breast Cancer Predictive Genetic Testing Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Breast Cancer Predictive Genetic Testing (Price)
      • 5.3.1. Global Breast Cancer Predictive Genetic Testing by: Type (Price)
  • 6. Breast Cancer Predictive Genetic Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. PerkinElmer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Quest Diagnostics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Myriad Genetics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cancer Genetics, Inc. (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. OncoCyte Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. NeoGenomics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Breast Cancer Predictive Genetic Testing Sale, by Type, Application and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Breast Cancer Predictive Genetic Testing (Value)
      • 7.2.1. Global Breast Cancer Predictive Genetic Testing by: Type (Value)
        • 7.2.1.1. High Penetrant Genes
        • 7.2.1.2. Intermediate Penetrant Genes
        • 7.2.1.3. Low Penetrant Genes
      • 7.2.2. Global Breast Cancer Predictive Genetic Testing by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinic Center
        • 7.2.2.3. Pharmaceuticals
        • 7.2.2.4. Research institutes
        • 7.2.2.5. Diagnostics laboratories
      • 7.2.3. Global Breast Cancer Predictive Genetic Testing Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Breast Cancer Predictive Genetic Testing (Price)
      • 7.3.1. Global Breast Cancer Predictive Genetic Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Breast Cancer Predictive Genetic Testing: by Type(USD Million)
  • Table 2. Breast Cancer Predictive Genetic Testing High Penetrant Genes , by Region USD Million (2016-2021)
  • Table 3. Breast Cancer Predictive Genetic Testing Intermediate Penetrant Genes , by Region USD Million (2016-2021)
  • Table 4. Breast Cancer Predictive Genetic Testing Low Penetrant Genes , by Region USD Million (2016-2021)
  • Table 5. Breast Cancer Predictive Genetic Testing: by Application(USD Million)
  • Table 6. Breast Cancer Predictive Genetic Testing Hospitals , by Region USD Million (2016-2021)
  • Table 7. Breast Cancer Predictive Genetic Testing Clinic Center , by Region USD Million (2016-2021)
  • Table 8. Breast Cancer Predictive Genetic Testing Pharmaceuticals , by Region USD Million (2016-2021)
  • Table 9. Breast Cancer Predictive Genetic Testing Research institutes , by Region USD Million (2016-2021)
  • Table 10. Breast Cancer Predictive Genetic Testing Diagnostics laboratories , by Region USD Million (2016-2021)
  • Table 11. South America Breast Cancer Predictive Genetic Testing, by Country USD Million (2016-2021)
  • Table 12. South America Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 13. South America Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 14. Brazil Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 15. Brazil Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 16. Argentina Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 17. Argentina Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 18. Rest of South America Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 19. Rest of South America Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 20. Asia Pacific Breast Cancer Predictive Genetic Testing, by Country USD Million (2016-2021)
  • Table 21. Asia Pacific Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 22. Asia Pacific Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 23. China Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 24. China Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 25. Japan Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 26. Japan Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 27. India Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 28. India Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 29. South Korea Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 30. South Korea Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 31. Taiwan Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 32. Taiwan Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 33. Australia Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 34. Australia Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 35. Rest of Asia-Pacific Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 36. Rest of Asia-Pacific Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 37. Europe Breast Cancer Predictive Genetic Testing, by Country USD Million (2016-2021)
  • Table 38. Europe Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 39. Europe Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 40. Germany Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 41. Germany Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 42. France Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 43. France Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 44. Italy Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 45. Italy Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 46. United Kingdom Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 47. United Kingdom Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 48. Netherlands Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 49. Netherlands Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 50. Rest of Europe Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 51. Rest of Europe Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 52. MEA Breast Cancer Predictive Genetic Testing, by Country USD Million (2016-2021)
  • Table 53. MEA Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 54. MEA Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 55. Middle East Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 56. Middle East Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 57. Africa Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 58. Africa Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 59. North America Breast Cancer Predictive Genetic Testing, by Country USD Million (2016-2021)
  • Table 60. North America Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 61. North America Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 62. United States Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 63. United States Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 64. Canada Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 65. Canada Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 66. Mexico Breast Cancer Predictive Genetic Testing, by Type USD Million (2016-2021)
  • Table 67. Mexico Breast Cancer Predictive Genetic Testing, by Application USD Million (2016-2021)
  • Table 68. Breast Cancer Predictive Genetic Testing: by Type(USD/Units)
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Breast Cancer Predictive Genetic Testing: by Type(USD Million)
  • Table 78. Breast Cancer Predictive Genetic Testing High Penetrant Genes , by Region USD Million (2022-2027)
  • Table 79. Breast Cancer Predictive Genetic Testing Intermediate Penetrant Genes , by Region USD Million (2022-2027)
  • Table 80. Breast Cancer Predictive Genetic Testing Low Penetrant Genes , by Region USD Million (2022-2027)
  • Table 81. Breast Cancer Predictive Genetic Testing: by Application(USD Million)
  • Table 82. Breast Cancer Predictive Genetic Testing Hospitals , by Region USD Million (2022-2027)
  • Table 83. Breast Cancer Predictive Genetic Testing Clinic Center , by Region USD Million (2022-2027)
  • Table 84. Breast Cancer Predictive Genetic Testing Pharmaceuticals , by Region USD Million (2022-2027)
  • Table 85. Breast Cancer Predictive Genetic Testing Research institutes , by Region USD Million (2022-2027)
  • Table 86. Breast Cancer Predictive Genetic Testing Diagnostics laboratories , by Region USD Million (2022-2027)
  • Table 87. South America Breast Cancer Predictive Genetic Testing, by Country USD Million (2022-2027)
  • Table 88. South America Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 89. South America Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 90. Brazil Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 91. Brazil Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 92. Argentina Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 93. Argentina Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 94. Rest of South America Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 95. Rest of South America Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 96. Asia Pacific Breast Cancer Predictive Genetic Testing, by Country USD Million (2022-2027)
  • Table 97. Asia Pacific Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 98. Asia Pacific Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 99. China Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 100. China Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 101. Japan Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 102. Japan Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 103. India Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 104. India Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 105. South Korea Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 106. South Korea Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 107. Taiwan Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 108. Taiwan Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 109. Australia Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 110. Australia Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 111. Rest of Asia-Pacific Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 112. Rest of Asia-Pacific Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 113. Europe Breast Cancer Predictive Genetic Testing, by Country USD Million (2022-2027)
  • Table 114. Europe Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 115. Europe Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 116. Germany Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 117. Germany Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 118. France Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 119. France Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 120. Italy Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 121. Italy Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 122. United Kingdom Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 123. United Kingdom Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 124. Netherlands Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 125. Netherlands Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 126. Rest of Europe Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 127. Rest of Europe Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 128. MEA Breast Cancer Predictive Genetic Testing, by Country USD Million (2022-2027)
  • Table 129. MEA Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 130. MEA Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 131. Middle East Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 132. Middle East Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 133. Africa Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 134. Africa Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 135. North America Breast Cancer Predictive Genetic Testing, by Country USD Million (2022-2027)
  • Table 136. North America Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 137. North America Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 138. United States Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 139. United States Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 140. Canada Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 141. Canada Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 142. Mexico Breast Cancer Predictive Genetic Testing, by Type USD Million (2022-2027)
  • Table 143. Mexico Breast Cancer Predictive Genetic Testing, by Application USD Million (2022-2027)
  • Table 144. Breast Cancer Predictive Genetic Testing: by Type(USD/Units)
  • Table 145. Research Programs/Design for This Report
  • Table 146. Key Data Information from Secondary Sources
  • Table 147. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Breast Cancer Predictive Genetic Testing: by Type USD Million (2016-2021)
  • Figure 5. Global Breast Cancer Predictive Genetic Testing: by Application USD Million (2016-2021)
  • Figure 6. South America Breast Cancer Predictive Genetic Testing Share (%), by Country
  • Figure 7. Asia Pacific Breast Cancer Predictive Genetic Testing Share (%), by Country
  • Figure 8. Europe Breast Cancer Predictive Genetic Testing Share (%), by Country
  • Figure 9. MEA Breast Cancer Predictive Genetic Testing Share (%), by Country
  • Figure 10. North America Breast Cancer Predictive Genetic Testing Share (%), by Country
  • Figure 11. Global Breast Cancer Predictive Genetic Testing: by Type USD/Units (2016-2021)
  • Figure 12. Global Breast Cancer Predictive Genetic Testing share by Players 2021 (%)
  • Figure 13. Global Breast Cancer Predictive Genetic Testing share by Players (Top 3) 2021(%)
  • Figure 14. Global Breast Cancer Predictive Genetic Testing share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Roche (United States) Revenue, Net Income and Gross profit
  • Figure 17. Roche (United States) Revenue: by Geography 2021
  • Figure 18. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 19. Thermo Fisher Scientific (United States) Revenue: by Geography 2021
  • Figure 20. PerkinElmer (United States) Revenue, Net Income and Gross profit
  • Figure 21. PerkinElmer (United States) Revenue: by Geography 2021
  • Figure 22. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 23. Quest Diagnostics (United States) Revenue: by Geography 2021
  • Figure 24. Myriad Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 25. Myriad Genetics (United States) Revenue: by Geography 2021
  • Figure 26. Cancer Genetics, Inc. (Italy) Revenue, Net Income and Gross profit
  • Figure 27. Cancer Genetics, Inc. (Italy) Revenue: by Geography 2021
  • Figure 28. OncoCyte Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 29. OncoCyte Corporation (United States) Revenue: by Geography 2021
  • Figure 30. NeoGenomics (United States) Revenue, Net Income and Gross profit
  • Figure 31. NeoGenomics (United States) Revenue: by Geography 2021
  • Figure 32. Global Breast Cancer Predictive Genetic Testing: by Type USD Million (2022-2027)
  • Figure 33. Global Breast Cancer Predictive Genetic Testing: by Application USD Million (2022-2027)
  • Figure 34. South America Breast Cancer Predictive Genetic Testing Share (%), by Country
  • Figure 35. Asia Pacific Breast Cancer Predictive Genetic Testing Share (%), by Country
  • Figure 36. Europe Breast Cancer Predictive Genetic Testing Share (%), by Country
  • Figure 37. MEA Breast Cancer Predictive Genetic Testing Share (%), by Country
  • Figure 38. North America Breast Cancer Predictive Genetic Testing Share (%), by Country
  • Figure 39. Global Breast Cancer Predictive Genetic Testing: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Roche (United States)
  • Thermo Fisher Scientific (United States)
  • PerkinElmer (United States)
  • Quest Diagnostics (United States)
  • Myriad Genetics (United States)
  • Cancer Genetics, Inc. (Italy)
  • OncoCyte Corporation (United States)
  • NeoGenomics (United States)
Select User Access Type

Key Highlights of Report


Apr 2022 221 Pages 69 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Breast Cancer Predictive Genetic Testing Quantitative research analysis
Global Breast Cancer Predictive Genetic Testing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Roche (United States), Thermo Fisher Scientific (United States), PerkinElmer (United States), Quest Diagnostics (United States), Myriad Genetics (United States), Cancer Genetics, Inc. (Italy), OncoCyte Corporation (United States) and NeoGenomics (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates Breast Cancer Predictive Genetic Testing Market to reach USD Million by 2027.

Know More About Global Breast Cancer Predictive Genetic Testing Report?

Have a Query? Click Here

Other Related Reports

Adenovirus Vaccine Comprehensive Study by Type (Type 4 Vaccine, Type 7 Vaccine), Application (Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others) Players and Region - ...
$ 3500
Allergic Rhinitis Drugs Comprehensive Study by Type (Corticosteroids, Antihistamines, Vasoconstrictors, Pratropium Bromide, Others (Leukotrienes, Cromoglycate)), Application (Non-Allergic Rhinitis, M...
$ 3650
Dental Drugs Comprehensive Study by Type (Analgesic, Anesthetics, Antibiotics, Antifungals, Antiseptics, Fluorides, Benzodiazepines, Saliva Substitutes), Mode of Administration (Injectable, Oral, Spr...
$ 3450
Clarityne Comprehensive Study by Type (Loratadine Tablet, Loratadine Capsule, Loratadine Syrup), Application (Adult Drug, Pediatric Drug), Sales Channel (Hospitals, Drug Store, Specialty Pharmacy, E-...
$ 3500
General Anesthesia Drugs Comprehensive Study by Type (Propofol, Dexmedetomidine, Sevoflurane, Desflurane, Midazolam, Others), Application (Inhalational Anesthetics, Intravenous Anesthetics), Distribu...
$ 3650
Zinc Gluconate Comprehensive Study by Application (Food, Pharmaceutical, Feed, Other), Distribution Channels (Online Pharmacies, Medical Stores, Hospital Pharmacies, Others), Dosage Form (Tablets, In...
$ 3650